Upregulation of interleukin 21 and promotion of interleukin 17 production in chronic or recurrent Vogt-Koyanagi-Harada Disease

Archives of Ophthalmology

Volumn 128, Issue 11, 2010, Pages 1449-1454

  Li, Fuzhen ^a,b   Yang, Peizeng ^b   Liu, Xiaoli ^b,c   Wang, Chaokui ^b   Hou, Shengping ^b   Kijlstra, Aize ^d  

^a SUN YAT SEN UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c JILIN UNIVERSITY   (China)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 21; MESSENGER RNA; PREDNISONE;

ADULT; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CHRONIC DISEASE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROL GROUP; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IN VITRO STUDY; MALE; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RECURRENT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; VOGT KOYANAGI SYNDROME;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CHRONIC DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKINS; LEUKOCYTES, MONONUCLEAR; MALE; RECOMBINANT PROTEINS; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UVEOMENINGOENCEPHALITIC SYNDROME;

EID: 78149474812     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2010.265     Document Type: Article

References (27)

1. Read RW, Rao NA, Cunningham ET. Vogt-Koyanagi-Harada disease. Curr Opin Ophthalmol. 2000;11(6):437-442.
2. Li B, Yang P, Zhou H, et al. Upregulation of T-bet expression in peripheral blood mononuclear cells during Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 2005;89(11):1410-1412. (Pubitemid 41527370)
3. + T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens. Invest Ophthalmol Vis Sci. 2006;47(6):2547-2554.
4. + T cells to produce IL-17 in Vogt-Koyanagi-Harada disease. J Allergy Clin Immunol. 2007;119(5):1218-1224.
5. Fina D, Sarra M, Fantini MC, et al. Regulation of gut inflammation and Th17 cell response by interleukin-21. Gastroenterology. 2008;134(4):1038-1048.
6. Liu Z, Yang L, Cui Y, et al. Il-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15(8):1133-1144.
7. (H)17 cells. Nature. 2007;448(7152):484- 487.
8. Nurieva R, Yang XO, Martinez G, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature. 2007;448(7152):480-483.
9. Spolski R, Kashyap M, Robinson C, Yu Z, Leonard WJ. IL-21 signaling is critical for the development of type I diabetes in the NOD mouse. Proc Natl Acad Sci U S A. 2008;105(37):14028-14033.
10. Spolski R, Leonard WJ. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol. 2008;26:57-79.
11. Monteleone G, Monteleone I, Fina D, et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-γ production in Crohn's disease. Gastroenterology. 2005;128(3):687-694. (Pubitemid 40585371)
12. Young DA, Hegen M, Ma HL, et al. Blockade of the interleukin-21/ interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum. 2007;56(4):1152-1163.
13. Li J, Shen W, Kong K, Liu Z. Interleukin-21 induces T-cell activation and proinflammatory cytokine secretion in rheumatoid arthritis. Scand J Immunol. 2006;64(5):515-522.
14. Caruso R, Botti E, Sarra M, et al. Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med. 2009;15(9):1013-1015.
15. Jones JL, Phuah CL, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest. 2009;119(7):2052-2061.
16. Distler JH, Jüngel A, Kowal-Bielecka O, et al. Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum. 2005;52(3):856-864. (Pubitemid 40365109)
17. Wang XF, Yuan SL, Jiang L, et al. Changes of serum BAFF and IL-21 levels in patients with systemic lupus erythematosus and their clinical significance [in Chinese]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2007;23(11):1041-1042.
18. Herber D, Brown TP, Liang S, Young DA, Collins M, Dunussi-Joannopoulos K. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J Immunol. 2007;178(6):3822-3830.
19. Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131(5):647-652.
20. Ozaki K, Spolski R, Ettinger R, et al. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol. 2004;173(9):5361-5371.
21. Yuan SL, Jiang L, Zhang XL, Li SF, Duan HM, Wang XF. Serum IL-21 level in patients with primary Sjogren's syndrome and clinical significance of IL-21 [in Chinese. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2007;23(2):124-126.
22. Caprioli F, Sarra M, Caruso R, et al. Autocrine regulation of IL-21 production in human T lymphocytes. J Immunol. 2008;180(3):1800-1807.
23. Chatterjee R, Batra J, Ghosh B. A common exonic variant of interleukin21 confers susceptibility to atopic asthma. Int Arch Allergy Immunol. 2009;148(2):137-146.
24. Bubier JA, Sproule TJ, Foreman O, et al. A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc Natl Acad Sci U S A. 2009;106(5):1518-1523.
25. Sonderegger I, Kisielow J, Meier R, King C, Kopf M. IL-21 and IL-21R are not required for development of Th17 cells and autoimmunity in vivo. Eur J Immunol. 2008;38(7):1833-1838.
26. Wurster AL, Rodgers VL, Satoskar AR, et al. Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon γ-producing Th1 cells. J Exp Med. 2002;196(7):969-977.
27. King C, Tangye SG, Mackay CR. T follicular helper (TFH) cells in normal and dysregulated immune responses. Annu Rev Immunol. 2008;26:741-766. (Pubitemid 351600391)